Steward Partners Investment Advisory’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
VCM
VPM
N
Steward Partners Investment Advisory's ADMA Position: Q1 2026 in Review
Steward Partners Investment Advisory increased its ADMA Biologics (ADMA) stake by 288% in Q1 2026, buying an estimated $71K and bringing the position to 6,062 shares worth $54.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2734.
Steward Partners Investment Advisory first reported a position in ADMA in Q2 2019 and has held it in 28 quarters since. The position peaked at $228K in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.
- Steward Partners Investment Advisory held 6,062 shares of ADMA Biologics worth $54.6K as of Q1 2026.
- Steward Partners Investment Advisory bought 4,500 ADMA Biologics shares in Q1 2026, an estimated $71K.
- ADMA Biologics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #2734 holding.
- Steward Partners Investment Advisory first reported a position in ADMA Biologics in Q2 2019 and has held it in 28 quarters since.
- Steward Partners Investment Advisory's ADMA Biologics position peaked at $228K in Q3 2024.
- 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.
Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.